JP2021121584A - Motor function-improving composition and activity-promoting composition - Google Patents

Abstract

To provide novel motor function-improving compositions that can efficiently improve motor function, and to provide novel activity-promoting compositions that can efficiently promote activity.SOLUTION: Provided is a motor function-improving composition or an activity-promoting composition, the composition containing a bacterium belonging to the Bifidobacterium longum subspecies infantis. Preferably the composition is a food or drink composition. Preferably the bacterium is Bifidobacterium longum subspecies Infantis M-63 (NITE BP-02623).SELECTED DRAWING: None

Description

The present invention relates to a composition for improving motor function and a composition for promoting activity.

In modern times, it is recommended to exercise moderately to maintain health and relieve stress. Then, in order to improve athletic ability, there is known a method of not only exercising but also supplementing nutrition by using an appropriate diet and supplements in combination. From the viewpoint of more efficiently improving athletic ability, a search for a component having an athletic ability improving action is being carried out.

It is known that some bifidobacteria, lactic acid bacteria, and the like can have various useful effects such as intestinal regulation, improvement of immune function, and improvement of athletic ability as probiotics. For example, Patent Document 1 describes that administration of the lactic acid bacterium Lactobacillus gasseri OLL2809 promotes physical activity.

Japanese Unexamined Patent Publication No. 2016-8345

An object of the present invention is to provide a new composition for improving motor function capable of efficiently improving motor function, and a new composition for promoting activity capable of efficiently promoting activity. ..

The present invention relates to [1] to [12] exemplified below.
[1] A composition for improving motor function, which contains a bacterium belonging to Bifidobacterium longum subspecies infantis.
[2] A composition for promoting activity, which contains a bacterium belonging to Bifidobacterium longum subspecies infantis.
[3] The composition according to [1] or [2], which is a food and drink composition.
[4] The composition according to any one of [1] to [3], wherein the bacterium is Bifidobacterium Longum Subspecies Infantis M-63 (NITE BP-02623).
[5] The composition according to any one of [1] to [4], wherein the bacterium is a live bacterium.
[6] The composition according to any one of [1] to [5], further comprising a human milk oligosaccharide.
[7] The composition according to any one of [1] to [6], which is prepared milk powder or prepared liquid milk.
[8] A motor function improver or an activity promoter containing a bacterium belonging to Bifidobacterium longum subspecies infantis.
[9] Use of bacteria belonging to Bifidobacterium Longum Subspecies Infantis for improving motor function or promoting activity.
[10] Bacteria belonging to Bifidobacterium longum subspecies infantis used for improving motor function or promoting activity.
[11] Use of bacteria belonging to Bifidobacterium longum subspecies infantis in the production of a composition for improving motor function or a composition for promoting activity.
[12] A method for improving motor function or promoting activity, which comprises a step of administering a bacterium belonging to Bifidobacterium Longum Subspecies Infantis to a mammal.

According to the present invention, it is possible to provide a new composition for improving motor function capable of improving motor function and a new composition for promoting activity capable of promoting activity.

It is a graph which shows the time required for a mouse to move a certain distance (20 m) in Experiment 1. A significant difference test for the control group was performed using student's t-test. * Is p <0.05. It is a graph which shows the time required for a mouse to move to a scaffold in Experiment 2. A significant difference test for the control group was performed using student's t-test. * Is p <0.05.

<Motor function improving agent and composition for improving motor function>
The motor function improving agent of the present invention includes bacteria belonging to Bifidobacterium longum subspecies infantis. The motor function improving agent of the present invention can improve the motor function of an ingested or administered subject.

The composition according to one embodiment of the present invention is a composition for improving motor function and includes a bacterium belonging to Bifidobacterium longum subspecies infantis. The composition for improving motor function of the present invention specifically contains the motor function improving agent of the present invention. The motor function improving agent of the present invention itself may be the composition for improving the motor function of the present invention. The composition for improving motor function of the present invention can improve the motor function of an ingested or administered subject.

In the present specification, "improvement of motor function" is not particularly limited in mode, but suppression of improvement or decrease in endurance that enables continuous exercise under aerobic or anaerobic exercise. A mode in which athletic ability is maintained or improved by increasing the amount of exercise, suppressing the improvement or decrease of muscle function (muscle strength), suppressing muscle fatigue, strengthening the contractile force of muscles, suppressing the increase or decrease of muscle mass, etc. Is included. It also includes aspects of weight loss or visceral fat mass loss due to maintenance or improvement of athletic performance.

Improvement of motor function includes improvement of daily activities, prevention or improvement of low back pain, prevention or improvement of muscle or joint tension, improvement of muscle or joint motility, improvement of physical flexibility, prevention of injury, etc. Aspects are included.

<Activity promoter and activity promoter composition>
The activity promoter of the present invention includes bacteria belonging to Bifidobacterium longum subspecies infantis. The activity promoter of the present invention can promote the activity of an ingested or administered subject.

The composition according to one embodiment of the present invention is an activity-promoting composition and contains a bacterium belonging to Bifidobacterium longum subspecies infantis. Specifically, the activity-promoting composition of the present invention contains the activity-promoting agent of the present invention. The activity-promoting agent of the present invention itself may be the activity-promoting composition of the present invention. The activity-promoting composition of the present invention can promote the activity of an ingested or administered subject.

In the present specification, "activity is promoted" is not particularly limited in mode, but includes an increase in physical activity, an increase in activity time, a decrease in visceral fat mass, and an increase in energy consumption. It includes aspects such as improvement of mental health, improvement of quality of life, and prevention of lifestyle-related diseases.

<Bacteria belonging to Bifidobacterium Longum Subspecies Infantis>
Bacteria belonging to Bifidobacterium Longum Subspecies Infantis are Gram-positive obligate anaerobic bacilli. As a bacterium belonging to Bifidobacterium longum subspecies infantis, one known or unknown bacterium belonging to Bifidobacterium longum subspecies infantis is used as long as the effect of the present invention is not impaired. Species or two or more species can be arbitrarily selected. Bifidobacterium longum subspecies infantis is sometimes referred to simply by the abbreviation Bifidobacterium infantis. Bacteria belonging to Bifidobacterium longum subspecies infantis include Bifidobacterium longum subspecies infantis BCCM LMG23728, Bifidobacterium longum subspecies infantis M- 63 (NITE BP-02623) and the like can be mentioned.

Bifidobacterium Longum Subspecies Infantis BCCM LMG23728 is a Belgian conservation agency, Belgium Coordinated Collections of Microorganisms (BCCM) (Address: Belgium, B-1000 Brussels Cyance Street (Watens Cup Street) 8) It can be obtained from.

Bifidobacterium Longum Subspecies Infantis M-63 (NITE BP-02623) was launched on January 26, 2018 by the National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (〒292-0818 Chiba). An international deposit was made based on the Budapest Treaty with the NITE BP-02623 accession number in Room 2-5-8 122, Kazusakamatari, Kisarazu City, Chiba Prefecture. Bifidobacterium longum subspecies infantis BCCM LMG23728 and Bifidobacterium longum subspecies infantis M-63 (NITE BP-02623) are substantially the same bacterium. ..

The bacterial shape of Bifidobacterium Longum Subspecies Infantis M-63 is bacillus or bifurcated polymorphism, with no spore formation and no motility. When this bacterium is applied onto a flat plate of BL agar medium and cultured at 37 ° C. for 48 hours in an anaerobic state, colonies having an opaque circular hemispherical luster are formed. Bifidobacterium longum subspecies infantis M-63 is fertile to arabinose, xylose, glucose, fructose, galactose, sucrose, maltose, lactose, mebilios, raffinose and turanose.

Bacteria belonging to Bifidobacterium longum subspecies infantis contained in the composition or agent according to the present invention may contain substantially the same bacteria as the above-mentioned deposited strain. Bacteria that are substantially the same as the deposited strain include, for example, a derivative strain having the deposited strain as the parent strain. Derivative strains include strains bred from the depositary strains and strains naturally occurring from the depositary strains.

As used herein, the term "substantially identical bacterium" refers to a bacterium of the same genus or species, in which the base sequence of the 16S rRNA gene is 98% or more, preferably 99%, or more than the base sequence of the 16S rRNA gene of the bacterium. As described above, it is more preferably a bacterium having 100% identity and preferably having the same mycological properties as the bacterium. Bacteria that are substantially the same are (1) bacteria that are determined to be the same strain by the RAPD (Randomly Amplified Polymorphic DNA) method or the PFGE (Pulsed-field gel electronics) method. (Described in 85 Page43), (2) Bacteria that carry only the gene derived from the bacterial strain, do not have the gene derived from the foreign country, and have a DNA identity of 95% or more, or (3) mutated from the bacterial strain. Strains (including genetically engineered modifications, mutations, spontaneous mutations, and may be bacteria with the same traits.

Bacteria belonging to Bifidobacterium longum subspecies infantis contained in the composition or agent according to the present invention may be live or dead, and both live and dead. However, it is preferably a live bacterium. The killed bacterium may be a crushed product. Additional operations such as heating or freeze-drying may be performed after culturing as long as the effects of the present invention are not impaired. It is preferable that the additional operation is such that the viable bacteria have a high survivability.

Bacteria belonging to Bifidobacterium longum subspecies infantis contained in the composition or agent according to the present invention appropriately change the method usually used for culturing Bifidobacterium spp. Can be cultivated. The culture temperature may be, for example, 25 to 50 ° C, preferably 30 to 40 ° C. The culture is preferably carried out under anaerobic conditions, and can be cultured while aerating an anaerobic gas such as carbon dioxide. The pH of the medium is not particularly limited as long as the bacterium can grow, but is, for example, pH 6.0 to 8.0.

The medium for culturing the bacteria belonging to Bifidobacterium longum subspecies infantis contained in the composition or agent according to the present invention is not particularly limited, and a medium usually used for culturing the bacteria is required. It can be changed and used as appropriate. As the carbon source of the medium, for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolyzate, and waste sugar honey can be used depending on the assimilation property. As the nitrogen source of the medium, for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride and ammonium nitrate and nitrates can be used. As the inorganic salts of the medium, for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate and the like can be used. In addition, organic components such as peptone, soybean flour, defatted soybean meal, meat extract, and yeast extract may be used as the medium. As the prepared medium, for example, MRS medium can be preferably used.

Bacteria belonging to Bifidobacterium Longum Subspecies Infantis can be used to improve motor function or promote activity. Bacteria belonging to Bifidobacterium Longum Subspecies Infantis have been used for many years in foods, drugs, etc., and because they exist as good bacteria in the intestines of animals. It is expected to be highly safe for living organisms. In addition, since it is considered that side effects and dependence are unlikely to occur, it is possible to take it continuously for a long period of time, and the target of application can easily take it.

The composition or agent according to the present invention may contain bacteria other than those belonging to Bifidobacterium longum subspecies infantis as long as it does not interfere with the motor function improving effect or activity promoting effect of the present invention. Bacteria that can be contained in the composition or agent according to the present invention include, for example, other bifidobacteria and lactic acid bacteria. Other Bifidobacterium spp. Examples include Bifidobacterium bifidam, Bifidobacterium longum subspecies longum, Bifidobacterium addresscentis, Bifidobacterium pseudocatenuratum, etc. Examples thereof include Bifidobacterium animalis subspecies lactis, Bifidobacterium breve, and Bifidobacterium pseudolonga. Examples of lactic acid bacteria include Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus ramnosus, Lactobacillus gasseri and the like.

The composition or agent according to the present invention may include a culture of bacteria belonging to Bifidobacterium longum subspecies infantis. The culture may be diluted or concentrated. Bacterial cultures can include bacterial secretions and metabolites.

<Food and drink composition>
The composition according to the present invention can be widely used as a medicine, a food or drink, and a feed. The composition is preferably taken orally or by tube, more preferably taken orally. The composition can be routinely ingested in the form of pharmaceuticals or foods and drinks. The composition of the present invention is preferably a food or drink composition.

The food and drink composition according to the present invention may be in the form of liquid, paste, solid, powder, etc., in addition to tablets, liquid foods, feeds (including those for pets), etc., for example, flour products, instant foods, agricultural products. Examples include processed products, processed marine products, processed livestock products, milk / dairy products, fats and oils, basic seasonings, complex seasonings / foods, frozen foods, confectionery, beverages, and other commercial products.

Examples of wheat flour products include bread crumbs, macaroni, spaghetti, noodles, cake mixes, fried chicken flour, bread crumbs and the like. Examples of instant foods include instant noodles, cup noodles, retort / cooked foods, canned foods, microwave foods, instant soups / stews, instant miso soup / soups, canned soups, freeze-dried foods, and other instant foods. .. Examples of processed agricultural products include canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, cereals (processed grain products), and the like. Examples of processed fishery products include canned fishery products, fish hams and sausages, fish paste products, fishery delicacies, and tsukudani. Examples of processed livestock products include canned livestock and pastes, livestock ham and sausage. Examples of milk and dairy products include fermented milk, processed milk, milk drinks, yogurts, lactic acid bacteria drinks, cheese, ice creams, formula milk powders, creams, and other dairy products. Examples of fats and oils include butter, margarines, vegetable oils and the like. Examples of the basic seasoning include soy sauce, miso, sauces, processed tomato seasonings, mirin, vinegar and the like. Examples of complex seasonings / foods include cooking mixes, curry ingredients, sauces, dressings, noodle soups, spices, and other complex seasonings. Examples of frozen foods include raw material frozen foods, semi-cooked frozen foods, and cooked frozen foods. Examples of confectioneries include caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, and other confectionery. Beverages include, for example, carbonated beverages, natural fruit juices, fruit juice beverages, soft beverages containing fruit juice, fruit meat beverages, fruit beverages containing fruit grains, vegetable beverages, soy milk, soy milk beverages, coffee beverages, tea beverages, powdered beverages, concentrated beverages, sports. Beverages, nutritional beverages, alcoholic beverages, other favorite beverages and the like can be mentioned. Examples of commercially available foods other than the above include baby foods, sprinkles, and Ochazuke seaweed.

The content of bacteria belonging to Bifidobacterium longum subspecies infantis in the food and drink composition is not particularly limited, and can be appropriately selected based on the daily intake. The content of bacteria belonging to Bifidobacterium longum subspecies infantis in the food and drink composition is, for example, 1 × 10 ⁶ to 1 × 10 ¹² cfu / g or 1 × 10 ⁶ to 1 × 10 ¹² cfu. It is preferably 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / g or 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / mL, more preferably 1 × 10 ⁸ to 1 × 10 ¹⁰ cfu. It is more preferably / g or 1 × 10 ⁸ to 1 × 10 ^{10 cfu / mL.} The unit cfu is an abbreviation for colony forming units and is a colony forming unit. If the bacterium is dead, cfu / g or cfu / mL can be replaced with individual cells / g or individual cells / mL.

The content of bacteria belonging to Bifidobacterium longum subspecies infantis in the food and drink composition can be arbitrarily set as long as the effects of the present invention are not impaired. The content of bacteria belonging to Bifidobacterium longum subspecies infantis in the food and drink composition is set to 0.3% by mass to 5.0% by mass with respect to the final composition of the food and drink composition. can do.

^{The intake of the food and drink composition is 1 × 10 6} to 1 × 10 ¹² cfu / day as the amount of bacteria belonging to Bifidobacterium longum subspecies infantis per 1 kg of body weight to be administered or ingested. Is preferable, 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / day is more preferable, and 1 × 10 ⁸ to 1 × 10 ¹⁰ cfu / day is even more preferable. If the bacterium is dead, cfu / day can be replaced with individual cells / day.

The food and drink composition may be prepared milk powder or prepared liquid milk. The formulas include infant formula or formula, follow-up formula or formula, low birth weight infant formula or formula, pediatric formula or formula, adult formula or Examples thereof include formula milk, formula milk for the elderly, formula milk for allergies, formula milk for allergies, formula milk for lactose intolerance, formula milk for congenital metabolic disorders, and formula milk for congenital metabolic disorders. The food and drink composition may be, in particular, infant formula or formula, follow-up formula or formula, formula for low birth weight infants or formula, pediatric formula or formula. preferable.

The composition can contain various additives depending on its type. The composition preferably comprises human milk oligosaccharides. Human milk oligosaccharide is a general term for oligosaccharides having trisaccharides or more excluding lactose contained in human milk. Mammalian milk contains 12 series of lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-hexaose (LNH), lacto-N-neohexaose (LNnH), etc. It has a core skeleton. By adding Lewis a, b, x and α2-3 / 2-6N-acetylneuraminic acid to these skeletons, there are as many as 100 variations in sugar chains. Human milk oligosaccharides are contained in breast milk at 10 to 20 g / L, and more than 130 types of oligosaccharides can be contained.

As the human milk oligosaccharide contained in the composition, any oligosaccharide that can be used by bacteria belonging to Bifidobacterium longum subspecies infantis is known or known as long as the effect of the present invention is not impaired. One or more unknown human milk oligosaccharides can be arbitrarily selected and used. Examples of human milk oligosaccharides include L-fucose, Lacto-N-fucopentaose I, Lacto-N-fucopentaose II, 2'-fucosyllactose, 3'-fucosyllactose, Lacto-N-fucopentaose III, 3'-Fucose III. hexaose, Lacto-N-difucohexaose I, Lacto-difucotetraose, Lactodifucohexaose I, Lactodifucohexaose II, Lacto-N-tetraose, Difucosyl syalyllacto-N-hexaose, Syalyllacto-N-tetraose, Fucosylsyalyl lacto-N-hexaose I, 3 ' -Fucosylsilyl lacto-N-tetrose (Fuc 1, 2, Gal, Fuc 1, 4 Gal NAC), Lacto-N-neotetraose, 3'-Siallyl-3-fucosyllactose, Disialomonofucosyla Sialyllacto-N-fucohexaose II, Disialyllacto-N-fucopentaose II, Monofucosyldisialyllacto-N-tetraose, 2'-Sialyllactose, 2'-Sialyllactosamine, 3'-Sialyllactose, 3'-Sialyllactosamine, 6'-Sialyllactose, 6'-Sialyllactosamine, Sialyllacto-N-neotetraose c, Monosialyllacto-N-hexaose, Disialyllacto-N-hexaose I, Monosialyllacto-N-neohexaose I, Monosialyllacto-N-neohexaose II, Disialyllacto-N-neohexaose, Disialyllacto-N-tetraose, Disialyllacto-N- hexaose II, Siallyl lacto-N-tetraose a, Digitallylacto-N-hexaose I, Sialyllacto-N-tetraose b, 2'-Fucossillacto-N-hexaose, 3'-Fucossillacto-N-neohexa N-fucosentaose V, Lacto-N-hexaose, Para-lacto-N-hexaose, Lacto-N-neohexaose, Para-lacto-N-neohexaose, Monofucosyllacto-N-hexaose II, , Isomeric fucosyllated lacto-N-hexaose (3), Isomeric fucosylated lacto-N-hexaose (2), Difucosyl-para-lacto-N-neohexaose, Diffa N-hexaose, Lacto-N-neocataose, Para-lacto-N-octanose, Iso-lacto-N-octaose, Lacto-N-octaose, Monofucosyllacto-neocataose, Monofa -N-octaose II, Difucosyllocto-N-neocataose II, Difucosyllacto-N-neocataose I, Lacto-N-decaose, Trifucosyllocto-N-neocate N-difuco-hexaose II, Siallyl-lacto-N-tetoraose a, Siallyl-lacto-N-tetraose b, Siallyl-lacto-N-tetoraose c, Siallyl-fuc Examples thereof include osyl-lacto-N-tetoraose I, Sialyl-fucosyl-lacto-N-tetoraose II, Digitalyl-lacto-N-tetoraose, Lacto-N-neottraose and the like. The compositions of the present invention preferably include 2'-fucosyllactose (hereinafter, also referred to as "2'-FL"), lacto-N-fucopentaose I (hereinafter, also referred to as "LNFPI"), and lacto-N-gif. It comprises at least one selected from cohexaose I (hereinafter also referred to as "LNDFP I") and lacto-N-tetraose (hereinafter also referred to as "LNnT").

2'-FL and LNnT have bifidobacteria growth activity and are known to act as growth factors for bifidobacteria by being selectively used by bifidobacteria. Important for formation. In addition, human milk oligosaccharides can be synthesized and can be used industrially.

The method for adding the human milk oligosaccharide is not particularly limited as long as the effect of the present invention is not impaired, and for example, the human milk oligosaccharide can be added and mixed after being liquid or powdered to produce the composition of the present invention.

The content of human milk oligosaccharide can be set arbitrarily as long as the effect of the present invention is not impaired. In the present invention, the content of human milk oligosaccharide in the composition can be set to 0.3% by mass to 5.0% by mass with respect to the final composition of the composition.

The composition may further comprise prebiotics. Prebiotics are indigestible food ingredients that have a beneficial effect on the host and improve the health of the host by selectively altering the growth and activity of specific bacteria in the large intestine. The prebiotics are not particularly limited as long as they do not impair the effects of the present invention, and for example, lactulose, raffinose, galactooligosaccharide, fructooligosaccharide, soybean oligosaccharide, milk fruit oligosaccharide, xylooligosaccharide, isomaluoligosaccharide, coffee bean mannooligo Sugar, gluconic acid, polydextrose, inulin and the like are preferable, among them, lactulose, raffinose, galactooligosaccharide and the like are more preferable, and lactulose, raffinose and galactooligosaccharide are further preferable.

The food or drink composition of the present invention can be produced by a method known to those skilled in the art, and is produced by adding a bacterium belonging to Bifidobacterium longum subspecies infantis to a known food or drink. Alternatively, it may be mixed with the raw material of the food or drink to produce a new food or drink composition. In addition to the steps of adding and mixing bacteria belonging to Bifidobacterium longum subspecies infantis, the production of food compositions includes a molding step, a sterilization step, a fermentation step, a baking step, a drying step, and a cooling step. , Granulation process, packaging process and the like can be combined as appropriate. Bacteria belonging to Bifidobacterium Longum Subspecies Infantis may be used as a starter for fermented milk production.

The content of bacteria belonging to Bifidobacterium longum subspecies infantis in the production of the composition is not particularly limited, but is, for example, 1 × 10 ⁶ to 1 × 10 ¹² cfu / g or 1 × 10 ⁶ to. It is preferably 1 × 10 ¹² cfu / mL, more preferably 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / g or 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / mL, and more preferably 1 × 10 ⁸ to 1 × 10 8 to mL. It is more preferably 1 × 10 ¹⁰ cfu / g or 1 × 10 ⁸ to 1 × 10 ^{10 cfu / mL.} If the bacterium is dead, cfu / g or cfu / mL can be replaced with individual cells / g or individual cells / mL.

The food and drink composition for improving motor function or the food and drink composition for promoting activity can be provided and sold as a food or drink labeled for health purposes such as improving athletic ability and promoting activity. Such indications are not particularly limited, but for example, "enhance motor function", "promote activity", "improve exercise amount", "endurance improvement", "increase physical activity amount", "activity time". "Increase in energy consumption", "Improvement of quality of life", "Prevention of lifestyle-related diseases". The act of "displaying" includes all actions for informing the consumer of the above-mentioned use, and if it is an expression that can recall or infer the above-mentioned use, the purpose of the display, the content of the display, and the display Regardless of the object, medium, etc., all fall under the "display" act of the present invention.

As the display content, it is preferable that the display is approved by the government or the like (for example, a display obtained based on various systems established by the government and performed in a manner based on such approval). In addition, it is preferable to attach such display contents to packaging, containers, catalogs, pamphlets, promotional materials such as POPs at sales sites, and other documents.

"Indication" also includes labeling as health foods, functional foods, enteric nutritional foods, special purpose foods, health functional foods, specified health foods, nutritional functional foods, functionally labeled foods, non-medicinal products, etc. Can be mentioned. Among these, in particular, labeling approved by the Consumer Affairs Agency, for example, a system related to foods for specified health use, nutritionally functional foods, or functionally labeled foods, or labeling approved by a system similar to these can be mentioned. Specifically, labeling as a food for specified health use, labeling as a food for specified health use with conditions, labeling as a food with functional claims, labeling to the effect that it affects the structure and function of the body, labeling for reducing the risk of illness, science Indication of functionality based on scientific evidence can be mentioned.

<Pharmaceutical composition>
The pharmaceutical composition is not particularly limited as long as it contains a bacterium belonging to Bifidobacterium longum subspecies infantis. The pharmaceutical composition may be produced by using bacteria belonging to Bifidobacterium longum subspecies infantis as they are, or by blending a physiologically acceptable liquid or a pharmaceutical carrier.

The dosage form of the pharmaceutical composition is not particularly limited, and it is formulated into a solid preparation such as a powder, a granule, a tablet, a capsule; a solution, a syrup, a suspension, a liquid such as an emulsion, a suppository, an ointment, etc. can do. At the time of formulation, a formulation carrier used for ordinary formulation can be used. In addition, the pharmaceutical composition can also contain a component having a motor function improving or activity promoting action known or found in the future.

The content of bacteria belonging to Bifidobacterium longum subspecies infantis in the pharmaceutical composition is not particularly limited, and it should be appropriately selected based on the daily intake or dose according to the dosage form. Can be done. The content of bacteria belonging to Bifidobacterium longum subspecies infantis in the pharmaceutical composition is, for example, 1 × 10 ⁶ to 1 × 10 ¹² cfu / g or 1 × 10 ⁶ to 1 × 10 ¹² cfu /. It is preferably 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / g or 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / mL, more preferably 1 × 10 ⁸ to 1 × 10 ¹⁰ cfu / mL. It is more preferably g or 1 × 10 ⁸ to 1 × 10 ^{10 cfu / mL.} If the bacterium is dead, cfu / g or cfu / mL can be replaced with individual cells / g or individual cells / mL.

^{The dose of the pharmaceutical composition is preferably 1 × 10 6} to 1 × 10 ¹² cfu / day as the amount of bacteria belonging to Bifidobacterium longum subspecies infantis per 1 kg of body weight of the subject to be administered. 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / day is more preferable, and 1 × 10 ⁸ to 1 × 10 ¹⁰ cfu / day is even more preferable. If the bacterium is dead, cfu / day can be replaced with individual cells / day. The method for administering the pharmaceutical composition may be oral administration or parenteral administration. The pharmaceutical composition may be administered once a day or in multiple doses.

As the pharmaceutical carrier, various organic or inorganic carriers can be used depending on the dosage form. Examples of the carrier in the case of a solid preparation include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents and the like.

Examples of excipients include sugar derivatives such as lactose, sucrose, glucose, mannit, and sorbit; starch derivatives such as corn starch, potato starch, α-starch, dextrin, and carboxymethyl starch; crystalline cellulose, hydroxypropyl cellulose, and hydroxy. Cellulous derivatives such as propylmethyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium; gum arabic; dextran; purulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; calcium carbonate Such as carbonate derivatives; sulfate derivatives such as calcium sulfate and the like can be mentioned.

Examples of the binder include gelatin, polyvinylpyrrolidone, and macrogol in addition to the above-mentioned excipients.

Examples of the disintegrant include, in addition to the above-mentioned excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, sodium carboxymethyl starch, and crosslinked polyvinylpyrrolidone.

Examples of the lubricant include talc; stearic acid; metal stearic acid salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and gay wax; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid; Carboxylic acid sodium salts such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as anhydrous silicic acid and silicic acid hydrate; starch derivatives and the like. ..

Examples of the stabilizer include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic acid anhydride; and sorbic acid.

Examples of the flavoring agent include sweeteners, acidulants, and flavors. Examples of the carrier used in the case of a liquid preparation for oral administration include a solvent such as water, a flavoring and odorant, and the like.

The pharmaceutical composition may be administered alone or may be administered by another drug, such as another drug for improving athletic performance or activity, an antipsychotic agent, anxiolytic agent, a hallucinogen, a mood stabilizer, a psychostimulant. , May be used in combination with sleeping pills and the like.

<How to improve motor function or promote activity>
A method of improving motor function or promoting activity involves administering to a mammal a bacterium belonging to Bifidobacterium Longum Subspecies Infantis. Bacteria belonging to Bifidobacterium longum subspecies infantis may be administered in the form of a composition containing the above-mentioned bacteria belonging to Bifidobacterium longum subspecies infantis.

Mammals include humans, cows, sheep, goats, pigs, dogs, cats, horses and the like. The administration subject may be an infant or a human infant. Infants include babies and toddlers, and more particularly include babies, toddlers and newborns, and more particularly include babies, toddlers, newborns, premature babies, preterm infants and low birth weight infants. In infants, by administering a bacterium belonging to Bifidobacterium longum subspecies infantis, the bacterium in the intestine is likely to grow, and an effect of improving motor function and an effect of promoting activity are likely to be obtained. In addition, the intestinal environment is easily adjusted by administering the bacterium during infancy.

In the present specification, the term "infant" refers to a child who is in infancy, and the term "infant" refers to a child who is under 1 year old (until the day before the day when he / she reaches 1 year old) from the time of birth when the subject is a human. It shall point. Infancy refers to the period when milk such as breast milk is the main source of nutrition.

In the present specification, the term "infant" refers to a child in early childhood, and the term "infant childhood" refers to the period from the day when the subject reaches the age of 1 to the time before entering school age when the subject is a human. .. Infancy is preferably from the day of reaching the age of 1 to the day of reaching the age of 6 or the day before the day of elementary school, whichever is earlier.

When the subject is a human, the composition or agent according to the present invention is preferably ingested or administered from birth to before entering school age. When the target is a mammal other than human, "school age" shall be read as "growth period".

When the subject is a human, the composition or agent according to the present invention is more preferably ingested or administered from the time of birth to less than 3 years old (until the day before the day when the child reaches 3 years old), and is more preferably administered to an infant. It is more preferably taken or administered during the period, and more preferably taken or administered from 3 months to less than 1 year old (until the day before the day when the baby reaches 1 year old). ..

When the target is a mammal other than a human, the relevant period may be converted into a period corresponding to these.
The "infant period" when the subject is a human corresponds to 20 days of age from birth in rats. Similarly, in cattle, it corresponds to the day before the day when the baby is 10 weeks old from the time of birth. In goats, it corresponds to the day before the day when the baby is 10 weeks old from birth. In sheep, it corresponds to the day before the day when the baby is 12 weeks old from the time of birth. In pigs, it corresponds to the day before the day when the pig is 8 weeks old from the time of birth. In monkeys, it corresponds to the day before the day when the baby is 14 weeks old from birth. In dogs, it corresponds to the day before the day when the dog is 6 weeks old from birth. In cats, it corresponds to the day before the day when the cat is 6 weeks old from the time of birth. In mice, it corresponds to 20 days of age from birth. In hamsters, it corresponds to 20 days of age from birth. In guinea pigs, it corresponds to 20 days of age from birth.

The "infant period" when the subject is a human corresponds to the day before the day when the age is 21 days to 5 weeks in the rat. Similarly, in cattle, it corresponds to the day before the day when the age is 10 weeks to 1 year. In the case of goats, it corresponds to the day before the day when the age of 10 weeks to 1 year old. In sheep, it corresponds to the day before the day when the age of 12 weeks to 1 year old. In pigs, it corresponds to the day before the day when the age is 8 weeks to 4 months. In monkeys, it corresponds to the day before the day when the age of 14 weeks to 1.5 years is reached. In dogs, it corresponds to the day before the day when the age is 6 weeks to 6 months. In cats, it corresponds to the day before the day when the age is 6 weeks to 6 months. In mice, it corresponds to the day before the day when the age is 21 days to 5 weeks. In hamsters, it corresponds to the day before the day when the age is 21 days to 5 weeks. In guinea pigs, it corresponds to the day before the day when the age is 21 days to 5 weeks.

"3 years old" when the subject is a human corresponds to 4 weeks old in a rat. Similarly, in cattle, it corresponds to 6 months of age. In goats, it corresponds to 6 months of age. In sheep, it corresponds to 6 months of age. In pigs, it corresponds to 3 months of age. In monkeys, it corresponds to 9 months of age. In dogs, it corresponds to 3 months of age. In cats, it corresponds to 3 months of age. In mice, it corresponds to 4 weeks of age. In hamsters, it corresponds to 4 weeks of age. In guinea pigs, it corresponds to 4 weeks of age.

"3 months full" when the subject is a human corresponds to 5 days old in rats. Similarly, in cattle, it corresponds to 2.5 weeks of age. In goats, it corresponds to 2.5 weeks of age. In sheep, it corresponds to the age of 3 weeks. In pigs, it corresponds to 2 weeks of age. In monkeys, it corresponds to 3 weeks of age. In dogs, it corresponds to 1.5 weeks of age. In cats, it corresponds to 1.5 weeks of age. In mice, it corresponds to 5 days of age. In hamsters, it corresponds to 5 days of age. In guinea pigs, it corresponds to 5 days of age.

"1 year old" when the subject is a human corresponds to 21 days old in a rat. Similarly, in cattle, it corresponds to the age of 10 weeks. In goats, it corresponds to 10 weeks of age. In sheep, it corresponds to 12 weeks of age. In pigs, it corresponds to 8 weeks of age. In monkeys, it corresponds to 14 weeks of age. In dogs, it corresponds to 6 weeks of age. In cats, it corresponds to 6 weeks of age. In mice, it corresponds to 21 days of age. In hamsters, it corresponds to 21 days of age. In guinea pigs, it corresponds to 21 days of age.

Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.

<Experiment 1>
C57BL / 6N mice were bred under the following conditions during the lactation period from the 5th day after birth to the 3rd week of weaning.
Comparative Example 1: The mice were cohabited with the mother mice and breast-fed.
Comparative Example 2: 100 μL / day of human breast milk was given.
Example 1: up to 2 weeks human milk 100 [mu] L / day in Bifidobacterium longum subsp infantis M-63 strain (. Hereinafter referred to as "M-63") of viable bacteria 5 × 10 ⁷ the food and drink composition was added, the second week onwards gave food or beverage composition plus viable 5 × 10 ⁸ of M-63 in human breast milk 100 [mu] L / day.

A motility evaluation test was conducted on mice that were weaned at the 3rd week after birth and bred up to the 7th week after birth. Seven-week-old immature mice were placed in a box having a plane size of 40 cm × 40 cm and allowed to move freely for 10 minutes. The illuminance was 20 lux. The moving distance and moving time when passing through the central portion 24 cm × 24 cm were measured by an infrared detection type motion sensor. The time required when the mouse continuously moved 20 m was calculated. The experiment was carried out with 13 individuals in Comparative Example 1, 16 individuals in Comparative Example 2, and 16 individuals in Example 1. The average time of each example and comparative example is shown in FIG.

As shown in FIG. 1, the time required for the mouse of Example 1 to travel a distance of 20 m was significantly shorter than that of the mouse of Comparative Example 1 and Comparative Example 2. Mice fed Bifidobacterium longum subspecies infantis are considered to have improved endurance, muscle function, etc. and / or increased activity, and improved motor function and / or activity. It was being promoted.

<Experiment 2>
In addition to the mice fed in the same manner as in Comparative Example 2 and Example 1 of Experiment 1, mice fed under the conditions of Comparative Example 3 below were prepared.
Comparative Example 3: Mice were breast-fed in the same manner as in Example 1 except that Bifidobacterium Animalis Subspecies Lactis MCC0115 was administered instead of M-63.

A water tank with a diameter of 90 cm was prepared, which was filled with water to a depth (30 cm) where the mouse legs could not touch. A scaffold is installed in the water tank at a distance of 40 cm from the starting point. Seven-week-old immature mice were placed in a water tank and the time required to reach the scaffold was measured. The experiment was performed under fluorescence. The experiment was carried out with 7 individuals in Comparative Example 2, 8 individuals in Example 1, and 8 individuals in Comparative Example 3. The average time of each example and comparative example is shown in FIG.

As shown in FIG. 2, the mouse of Example 1 took significantly shorter time to swim a distance of 40 cm than the mouse of Comparative Example 2 and Comparative Example 3. Mice fed Bifidobacterium longum subspecies infantis are considered to have improved endurance, muscle function, etc. and / or increased activity, and improved motor function and / or activity. It was being promoted. In addition, when other bacteria of the genus Bifidobacterium other than those derived from humans were ingested, the effect of improving motor function and / or promoting activity was not observed.

Claims (12)

A composition for improving motor function, which contains bacteria belonging to Bifidobacterium longum subspecies infantis. A composition for promoting activity, which contains a bacterium belonging to Bifidobacterium longum subspecies infantis. The composition according to claim 1 or 2, which is a food and drink composition. The composition according to any one of claims 1 to 3, wherein the bacterium is Bifidobacterium Longum Subspecies Infantis M-63 (NITE BP-02623). The composition according to any one of claims 1 to 4, wherein the bacterium is a live bacterium. The composition according to any one of claims 1 to 5, further comprising a human milk oligosaccharide. The composition according to any one of claims 1 to 6, which is prepared milk powder or prepared liquid milk. A motor function enhancer or activity promoter containing bacteria belonging to Bifidobacterium Longum Subspecies Infantis. Use of bacteria belonging to Bifidobacterium Longum Subspecies Infantis to improve motor function or promote activity. Bacteria belonging to Bifidobacterium longum subspecies infantis used to improve motor function or promote activity. Use of bacteria belonging to Bifidobacterium longum subspecies infantis in the manufacture of motor function enhancing compositions or activity promoting compositions. A method for improving motor function or promoting activity, which comprises the step of administering a bacterium belonging to Bifidobacterium Longum Subspecies Infantis to a mammal.

Images